An ICG fluorescence image measured with an excitation light of 740 nm and a fluorescence of 845 nm is shown in FIG. 10, and an ICG fluorescence image measured with an excitation light of 780 nm and a fluorescence of 845 nm is shown in FIG. 11, respectively. As a result, it was observed that the ICG derivative RGD2-PPA-Cy accumulated in the tumor tissue 30 minutes after tail vein administration, regardless of whether the wavelength of the excitation light was 740 nm or 780 nm.

A first aspect of the invention relates to novel compounds and more precisely to novel bifunctional prodrugs and drugs. An additional aspect of the invention relates to antibody compound conjugates, wherein the compound is a claimed compound, and to pharmaceutical compositions containing the compound or antibody compound conjugate. The invention lastly relates to the use of this compound or antibody compound conjugates according to the invention in order to treat tumour diseases, particularly in mammals.

A first aspect of the invention relates to novel compounds and more precisely to novel bifunctional prodrugs and drugs. An additional aspect of the invention relates to antibody compound conjugates, wherein the compound is a claimed compound, and to pharmaceutical compositions containing the compound or antibody compound conjugate. The invention lastly relates to the use of this compound or antibody compound conjugates according to the invention in order to treat tumour diseases, particularly in mammals.

Novel fluorescent compounds that can be used for labelling tumour tissue, and the method for labelling tumour tissue the novel fluorescent compounds. Also, the application of the tumour tissue labelled with the novel fluorescent compounds as a monitoring tool, a diagnostic tool, or a tool for assisting with cancer surgery.

This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.

This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.

Disclosed are a cyanine-derived compound, a preparation method therefor, and application thereof. The compound has the structure represented by formula (1), and the preparation method for the compound is further disclosed. The series of compounds of the present invention can be used as fluorescent markers for live-cell imaging analysis or flow cytometric analysis, solving problems of high toxicity, high cost and poor imaging effect of current.

##STR00001##

Disclosed are a cyanine-derived compound, a preparation method therefor, and application thereof. The compound has the structure represented by formula (1), and the preparation method for the compound is further disclosed. The series of compounds of the present invention can be used as fluorescent markers for live-cell imaging analysis or flow cytometric analysis, solving problems of high toxicity, high cost and poor imaging effect of current.

##STR00001##

To provide a compound having high TB and a contrast agent for optical imaging. The compound has a molecular weight of a specific range, the compound in which two polyethylene glycols are bonded to a specific cyanine pigment through a linker. The present invention provides a compound which has a high T/B and which can be used as a contrast agent capable of imaging a tumor portion with high contrast.

Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.